Mannatech Granted Injunction on Patents Related to Ambrotose(R) Product Infringed by Green Life and Xiong Lo

COPPELL, Texas, Dec 18, 2009 (BUSINESS WIRE) -- Mannatech, Incorporated (NASDAQ: MTEX ), a global pioneer in the development of high-quality health, weight and fitness, and skin care solutions based on nutritional science, obtained a judgment finding that Green Life, LLC (Green Life), and Xiong Lo /quotes/comstock/13*!lo/quotes/nls/lo (LO 78.44, -0.05, -0.06%) infringed Mannatech patents (U.S. Patents 6,929,807; 7,157,431; 7,196,064; 7,199,104; and 7,202,220).

Senior United States District Judge A. Joe Fish in the U.S. District Court for the Northern District of Texas, Dallas Division, issued a final judgment that entered a broad permanent injunction against Green Life and Lo prohibiting them from "making, using, offering to sell, selling, or otherwise distributing within the United States, or importing into the United States, defendant's product, Glyco 8, as well as products that are substantially equivalent in composition to Glyco 8, and any other products that infringe the patents in suit.(1)"

"This case underscores our commitment to pursuing injustice against the company and our core technologies. We will continue to do what is necessary to protect our intellectual property," said Keith Clark, Mannatech's executive vice president and chief legal officer.

On July 15, Mannatech filed a complaint for patent infringement alleging that Green Life and Xiong Lo infringed Mannatech's patents entitled "Compositions of Plant Technology as Dietary Supplements," through Green Life's purchase of the dietary supplement Glyco 8 from defendant Boston Mountain Laboratories, Inc. Mannatech also named Boston Mountain, the entity that actually manufactured the infringing product, as a defendant. Mannatech previously settled its claims against Boston Mountain through the entry of an agreed final judgment that enjoined Boston Mountain from manufacturing all products infringing on Mannatech patents in question.

Mannatech offers a comprehensive approach to wellness that addresses physical and financial health with cutting-edge, proprietary products based on the foundation of nutritional science and business opportunities for individuals around the world who seek purpose, financial freedom and a chance to impact the lives of others. The company has distinguished itself in the emerging glyconutrients market through the development of Ambrotose(R) complex, the technology for which it holds more than 45 patents in 30 countries. Glyconutrients are dietary ingredients containing beneficial amounts of carbohydrates which are believed to represent a new category of untapped vital nutrients for proper nutrition.

In addition, many of Mannatech's products are based on Real Food Technology(SM) solutions which provide consumers with products that contain standardized levels of natural and plant-sourced nutrients at nutritionally effective levels. Food-sourced ingredients are chosen from those scientifically proven to most benefit the human body. Mannatech offers the best alternative to synthetic vitamin and mineral products and so-called "super-juice" products.

Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at

About Mannatech

Mannatech, Incorporated develops high-quality health, weight and fitness, and skin care products that are based on the solid foundation of nutritional science and development standards. These proprietary products are available through independent sales Associates around the globe including the United States, Canada, South Africa, Australia, New Zealand, Austria, Denmark, Germany, Norway, Sweden, the Netherlands, the United Kingdom, Japan, Taiwan, Singapore and the Republic of Korea. For more information, please visit

(1) Case 3:09-cv-01324-G-BD, U.S. District Court, Northern District of Texas, Dallas Division, Filed 12/14/2009

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.